How to Improve Weak Signal Judgment

Everyone collects weak signals now. Most of what they collect predicts nothing. A weak signal isn't a thing you spot, it's a prediction you make, and the edge goes to whoever bets on it while being wrong is still cheap.

So how do you become the one placing the bet, not the one still collecting reports? Let's get into it.

What a Weak Signal Actually Is A weak signal is a faint piece of evidence that points to something a customer will want before they can name it, and before the market has priced it in. Faint, because if it were loud, everyone would already be acting on it. Deniable, because you can always explain it away as noise, and most people do. That deniability is the whole point. The moment it becomes undeniable, the advantage is gone and the price has moved.

Why Noticing Stopped Being the Edge Ten years ago, noticing was hard. You needed sources, a network, time to read widely, a feel for the edges of your industry. That was the moat. It isn't anymore. Every team has a trend report and three newsletters and an AI tool surfacing emerging behaviors on a schedule. The noticing got automated. What didn't get automated is the judgment about which signal predicts a structural change and which points to nothing real, and the nerve to act early.

Inside Roche's Innovation Board I sat on Roche's diagnostics innovation board, the only outsider in the room, helping decide which ideas got funded. At one point we took on diabetes care.

I am not diabetic. So I had Roche ship me every meter and test strip they made, and I pricked my finger up to a dozen times a day to feel what their customers felt. You cannot innovate for a customer whose day you have never lived. Skip that, and everything after is a guess.

Roche was a leader in blood glucose testing with its Accu-Chek meters, and the math looked obvious. Someone with type 1 diabetes tests around eight times a day, every day, for life. A big, stable business. Type 2 was the smaller story per patient. Those patients tested once, maybe twice a day, so each one looked worth less, and we filed the category under "less interesting." We could already see type 2 climbing. We weighed it against the per-patient math and explained it away.

Then type 2 diagnoses exploded into one of the fastest-growing chronic conditions in the world. And the category stopped being about counting tests per day at all, because monitoring went continuous, the always-on sensors people wear today. We had seen the early edge of both shift